Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31378330.
- Also identified by DOI 10.1016/j.mcna.2019.05.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oral anticoagulation significantly reduces the risk of stroke in patients with atrial fibrillation (AF), and the decision to initiate therapy is based on assessing the patient's yearly risk of stroke. Although warfarin remains the drug of choice in patients with AF and artificial mechanical valves, the novel anticoagulation agents are becoming the drug of choice for all other patients with AF, because of their efficacy, safety, and ease of use. This article summarizes the current evidence for stroke prevention in AF, including valvular AF, subclinical AF, AF in patients with renal insufficiency, as well as stroke prevention around AF cardioversion.
Medical subject headings
- Anticoagulants
- Atrial Fibrillation
- Stroke